Menarini, a big pharma company and Oxford BioTherapeutics announced a major innovative and strategic pharma partners alliance to develop a portfolio of antibody-based drugs in the field of cancer.
The pharma partners agreement covers five of antibody and antibody drug conjugate programs, each of which addresses a different cancer indication via a different novel oncology target.
Under this pharma partners collaboration, Menarini will lead the efforts in the manufacture and clinical development of each program, supported by OBT, while OBT will provide the proprietary cancer target, antibody and arming technologies.
Once clinical proof of concept has been achieved, OBT will complete the clinical development and commercialise these novel antibody-based products in North America and Japan, whilst Menarini will develop and commercialise the products in Europe, CIS, Asia and Latin America.
For further deal information visit Current Agreements (subscription required)
Read:more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Related reports: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity